WO2008049997A8 - Derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents

Derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Download PDF

Info

Publication number
WO2008049997A8
WO2008049997A8 PCT/FR2007/001708 FR2007001708W WO2008049997A8 WO 2008049997 A8 WO2008049997 A8 WO 2008049997A8 FR 2007001708 W FR2007001708 W FR 2007001708W WO 2008049997 A8 WO2008049997 A8 WO 2008049997A8
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
indole derivatives
medicaments
Prior art date
Application number
PCT/FR2007/001708
Other languages
English (en)
Other versions
WO2008049997A3 (fr
WO2008049997A2 (fr
Inventor
Pascal Marchand
Vincent Babonneau
Sylvie Piessard
Muriel Duflos
Jean Albert Boutin
Valerie Audinot
Philippe Delagrange
Daniel-Henri Caignard
Original Assignee
Servier Lab
Pascal Marchand
Vincent Babonneau
Sylvie Piessard
Muriel Duflos
Jean Albert Boutin
Valerie Audinot
Philippe Delagrange
Daniel-Henri Caignard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2009532844A priority Critical patent/JP2010506890A/ja
Priority to CA002666522A priority patent/CA2666522A1/fr
Priority to AU2007310770A priority patent/AU2007310770A1/en
Priority to EP07858468A priority patent/EP2079689A2/fr
Priority to EA200900481A priority patent/EA200900481A1/ru
Priority to BRPI0717528-0A priority patent/BRPI0717528A2/pt
Application filed by Servier Lab, Pascal Marchand, Vincent Babonneau, Sylvie Piessard, Muriel Duflos, Jean Albert Boutin, Valerie Audinot, Philippe Delagrange, Daniel-Henri Caignard filed Critical Servier Lab
Priority to US12/311,805 priority patent/US20100204276A1/en
Priority to MX2009004006A priority patent/MX2009004006A/es
Publication of WO2008049997A2 publication Critical patent/WO2008049997A2/fr
Publication of WO2008049997A3 publication Critical patent/WO2008049997A3/fr
Priority to NO20091779A priority patent/NO20091779L/no
Publication of WO2008049997A8 publication Critical patent/WO2008049997A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms

Abstract

Composés de formule (I) : dans laquelle : R1 représente un groupement alkyle, cycloalkyle ou cycloalkylalkyle, R2 et R3 forment ensemble avec l'atome d'azote qui les porte un hétérocycle comportant de 5 à 8 chaînons, et n représente 2 à 6, médicaments.
PCT/FR2007/001708 2006-10-18 2007-10-17 Derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent WO2008049997A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002666522A CA2666522A1 (fr) 2006-10-18 2007-10-17 Nouveaux derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2007310770A AU2007310770A1 (en) 2006-10-18 2007-10-17 New indole compounds, a process for their preparation and pharmaceutical compositions containing them
EP07858468A EP2079689A2 (fr) 2006-10-18 2007-10-17 Derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA200900481A EA200900481A1 (ru) 2006-10-18 2007-10-17 Новые соединения индола, способ их получения и фармацевтические композиции, которые их содержат
BRPI0717528-0A BRPI0717528A2 (pt) 2006-10-18 2007-10-17 Derivados indólicos, seu processo de preparação e as composições farmacêuticas que os contêm
JP2009532844A JP2010506890A (ja) 2006-10-18 2007-10-17 インドール誘導体、その製造法、およびそれを含有する薬学的組成物
US12/311,805 US20100204276A1 (en) 2006-10-18 2007-10-17 Indole compounds, a process for their preparation and pharmaceutical compositions containing them
MX2009004006A MX2009004006A (es) 2006-10-18 2007-10-17 Derivados de indol novedosos, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
NO20091779A NO20091779L (no) 2006-10-18 2009-05-06 Nye indolforbindelser en prosess for deres fremstilling og farmasoytiske sammensetninger som inneholder dem

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0609113 2006-10-18
FR0609113A FR2907451B1 (fr) 2006-10-18 2006-10-18 "nouveaux derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"

Publications (3)

Publication Number Publication Date
WO2008049997A2 WO2008049997A2 (fr) 2008-05-02
WO2008049997A3 WO2008049997A3 (fr) 2008-09-12
WO2008049997A8 true WO2008049997A8 (fr) 2009-05-22

Family

ID=38051392

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/001708 WO2008049997A2 (fr) 2006-10-18 2007-10-17 Derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Country Status (18)

Country Link
US (1) US20100204276A1 (fr)
EP (1) EP2079689A2 (fr)
JP (1) JP2010506890A (fr)
KR (1) KR20090084874A (fr)
CN (1) CN101522616A (fr)
AR (1) AR063328A1 (fr)
AU (1) AU2007310770A1 (fr)
BR (1) BRPI0717528A2 (fr)
CA (1) CA2666522A1 (fr)
EA (1) EA200900481A1 (fr)
FR (1) FR2907451B1 (fr)
GE (1) GEP20115240B (fr)
MA (1) MA30797B1 (fr)
MX (1) MX2009004006A (fr)
NO (1) NO20091779L (fr)
UA (1) UA91645C2 (fr)
WO (1) WO2008049997A2 (fr)
ZA (1) ZA200902414B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2488025A4 (fr) * 2009-10-15 2013-04-03 Childrens Medical Center Inhibiteurs de sépiaptérine réductase pour le traitement de la douleur
CN102219725B (zh) * 2010-04-16 2013-10-09 中国科学院上海药物研究所 苯并杂环类化合物及其制备方法和用途
ES2694049T3 (es) 2014-01-14 2018-12-17 Astellas Pharma Inc. Compuesto de indol
CN105085366A (zh) * 2014-05-07 2015-11-25 北京生命科学研究所 一种吲哚骨架化合物及其应用
RU2581711C1 (ru) * 2015-03-10 2016-04-20 Федеральное государственное бюджетное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Минздрава России ФГБУ "РНЦ "ВТО" им. акад. Г.А. Илизарова" Минздрава России Способ восстановления функции локтевого сустава при неправильно сросшихся переломах мыщелка плечевой кости
CN108299274B (zh) * 2018-02-08 2021-01-15 中国热带农业科学院海口实验站 一种天然吲哚，其制备方法及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2737725B1 (fr) * 1995-08-08 1997-10-31 Valentonine Nouveaux derives acyles de la melatonine et d'analogues melatoninergiques, leur procede de preparation et leur utilisation en tant que medicament

Also Published As

Publication number Publication date
UA91645C2 (ru) 2010-08-10
WO2008049997A3 (fr) 2008-09-12
FR2907451B1 (fr) 2008-12-12
CN101522616A (zh) 2009-09-02
WO2008049997A2 (fr) 2008-05-02
CA2666522A1 (fr) 2008-05-02
MX2009004006A (es) 2009-04-28
US20100204276A1 (en) 2010-08-12
AR063328A1 (es) 2009-01-21
JP2010506890A (ja) 2010-03-04
GEP20115240B (en) 2011-06-10
EA200900481A1 (ru) 2009-10-30
FR2907451A1 (fr) 2008-04-25
AU2007310770A1 (en) 2008-05-02
BRPI0717528A2 (pt) 2013-10-22
NO20091779L (no) 2009-05-06
EP2079689A2 (fr) 2009-07-22
ZA200902414B (en) 2010-07-28
KR20090084874A (ko) 2009-08-05
MA30797B1 (fr) 2009-10-01

Similar Documents

Publication Publication Date Title
EP1982982A4 (fr) Nouveau derive de coumarine ayant une activite antitumorale
TW200637869A (en) The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
WO2008114817A1 (fr) Nouveau composé d'adénine
WO2007061360A3 (fr) Nouveau composes
WO2008081096A3 (fr) Derives quinolinyliques, leur procede de preparation. les compositions pharmaceutiques qui les contiennent et leur utilisation comme agents hypoglycemiants et hypoli pemiants
TNSN05160A1 (en) Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
TW200616636A (en) Novel compounds
WO2007138472A3 (fr) Dérivés de la triazolopyridazine
WO2008006795A3 (fr) Composés d'indole
NO20083434L (no) Benzamid- og heteroarenderivater
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
WO2008006969A3 (fr) Nouveaux derives tetracycuques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2006117211A3 (fr) Derives d'uree, procedes pour leur fabrication et utilisations de ces derives
TW200626158A (en) Naphthaline derivatives
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
WO2008049997A3 (fr) Derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2008114812A1 (fr) Inhibiteur de jak
WO2007083060A3 (fr) Derives de chalcone a activite antimitotique
MY150497A (en) New camptothecin analogue compounds, a process for their preparation and pharmaceutical compositions containing them
SG168499A1 (en) New dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
WO2007080270A3 (fr) Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
TW200616635A (en) Novel compounds
WO2006002802A8 (fr) Derives phenyle comprenant un groupe acetylene
WO2006036007A3 (fr) Preparation a liberation modifiee
WO2004083185A3 (fr) Composes imidazole

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780037231.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07858468

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007858468

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 575826

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2102/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007310770

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2666522

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009040524

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/004006

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009532844

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007310770

Country of ref document: AU

Date of ref document: 20071017

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200900481

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 11251

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 1020097010133

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12311805

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0717528

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090416